tacrolimus

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Conditions

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Trial Timeline

Apr 1, 2014 → Dec 23, 2019

NCT ID

NCT02159651

About tacrolimus

tacrolimus is a pre-clinical stage product being developed by Astellas Pharma for Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT02159651. Target conditions include Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis.

What happened to similar drugs?

1 of 5 similar drugs in Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis were approved

Approved (1) Terminated (2) Active (3)

✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved

❌Mirabegron + PlaceboAstellas PharmaPhase 3

🔄Certican® + Neoral + Myfortic + Simulect® + CorticosteroidsNovartisPhase 3

🔄Certolizumab pegol + PlaceboUCBPhase 3

🔄Placebo + SeralutinibGossamer BioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00189761	Phase 2	Completed	—	—	Bone Marrow Transplantation
NCT00293930	Phase 3	Completed	—	Nov 1, 2006	Psoriasis
NCT00189787	Phase 2	Completed	—	Aug 1, 2005	Asthma, Bronchial
NCT00189722	Phase 2	Completed	—	Jul 1, 2005	Asthma, Bronchial
NCT03465969	Approved	Completed	Mar 20, 2018	Sep 14, 2018	Kidney Transplantation
NCT02555787	Pre-clinical	Completed	Mar 5, 2015	Sep 30, 2022	Kidney Transplantation
NCT02147938	Pre-clinical	Completed	Jul 17, 2014	May 15, 2017	Renal Transplantation
NCT02143479	Pre-clinical	Completed	Jun 18, 2014	May 3, 2017	Liver Transplantation
NCT02159651	Pre-clinical	Completed	Apr 1, 2014	Dec 23, 2019	Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis
NCT02057484	Pre-clinical	Completed	Mar 3, 2014	Oct 17, 2017	Liver Transplant
NCT02377609	Pre-clinical	Terminated	Oct 1, 2013	Sep 1, 2014	Validation
NCT01745159	Approved	Completed	Sep 1, 2012	Nov 1, 2013	Moderate/Severe Atopic Dermatitis
NCT01511003	Approved	Completed	Dec 5, 2011	May 11, 2015	Rheumatoid Arthritis
NCT01316133	Approved	Terminated	Apr 19, 2011	Apr 8, 2016	Lupus Nephritis
NCT01410162	Approved	Completed	Dec 1, 2010	Dec 1, 2014	Renal Transplant
NCT02963103	Approved	Terminated	May 1, 2010	Oct 1, 2012	Kidney Transplantation
NCT01224041	Approved	Completed	Aug 1, 2009	Jun 1, 2011	Rheumatoid Arthritis
NCT01224418	Approved	Completed	May 1, 2008	Aug 1, 2009	Rheumatoid Arthritis
NCT00504348	Phase 2/3	Completed	Jul 1, 2007	Jan 1, 2011	Interstitial Pneumonitis
NCT01410747	Pre-clinical	Completed	Apr 10, 2007	Jan 31, 2020	Lupus Nephritis

Competing Products

20 competing products in Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

See all competitors

Product	Company	Stage	Hype Score
Ferumoxytol + Gadobutrol	Lipella Pharmaceuticals	Phase 1	19
LP-08 80mg + Normal saline + LP-08 20mg	Lipella Pharmaceuticals	Phase 2	25
ASP3652 + Placebo	Astellas Pharma	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Phase 3	32
Tacrolimus	Astellas Pharma	Phase 2/3	38
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	42
Placebo + JNJ-42160443	Johnson & Johnson	Phase 2	27
Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mg	Johnson & Johnson	Approved	35
BOTOX + Placebo for BOTOX	AbbVie	Phase 2	35
NS-863 Low Dose + NS-863 High Dose	Nippon Shinyaku	Phase 2	42
INS316 solution for inhalation + hypertonic saline 3% sodium chloride solution	Merck	Phase 2	27
Abituzumab 1500 mg + Abituzumab 500 mg + Placebo	Merck	Phase 2	27
MK-2225 + Placebo	Merck	Phase 1	21
Certican® + Neoral + Myfortic + Simulect® + Corticosteroids	Novartis	Phase 3	40
Pirfenidone + Placebo	Roche	Phase 2	35
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685	Pfizer	Phase 2	35
Tanezumab + Tanezumab + Tanezumab + Tanezumab	Pfizer	Phase 2	27
ERB-041	Pfizer	Pre-clinical	18
PF-04383119 + Placebo	Pfizer	Phase 2	35
Abatacept	Bristol Myers Squibb	Phase 2	42